Otten T F, Solov'eva N S, Vishnevskiĭ B I
Research Institute of Phtisiopulmonology, Ministry of Health of Russian Federation, St-Petersburg.
Antibiot Khimioter. 2002;47(6):34-7.
Activity of levofloxacin (Tavanic) against 10 species of nontuberculosis of mycobacteria was investigated by indirect method of absolute concentrations on Levenstain-Jensen media (levofloxacin concentration 5 and mcg/mL). The investigation was performed on 71 strains of nontubercolosis mycobacteria: Mycobacterium avium-intracellulare--24 strains, M. fortuitum--17 strains, M. chelonae--10 strains, M. malmoense--13 strains and 6 other species of mycobacteria. Susceptible to critical levofloxacin concentration were 8 species of 10. Resistance to levofloxacin (10 mcg/mL) was estimated for 16.7 per cent of M. avium-intracellulare and 30 per cent of M. chelonei strains. It is concluded that levofloxacin may be a drug of choice for management of mycobacteriosis caused by M. fortuitum, M. kansasii, M. xenopi, M. malmoense, and in the most of cases due to M. avium-intracellulare and M. chelonae.
采用绝对浓度间接法在罗-琴培养基（左氧氟沙星浓度为5微克/毫升）上研究了左氧氟沙星（可乐必妥）对10种非结核分枝杆菌的活性。对71株非结核分枝杆菌进行了研究：鸟分枝杆菌-胞内分枝杆菌24株、偶然分枝杆菌17株、龟分枝杆菌10株、马尔默分枝杆菌13株以及其他6种分枝杆菌。10种中有8种对左氧氟沙星的临界浓度敏感。鸟分枝杆菌-胞内分枝杆菌的16.7%菌株和龟分枝杆菌的30%菌株对左氧氟沙星（10微克/毫升）耐药。得出的结论是，左氧氟沙星可能是治疗由偶然分枝杆菌、堪萨斯分枝杆菌、偶发分枝杆菌、马尔默分枝杆菌引起的分枝杆菌病的首选药物，在大多数情况下也是治疗由鸟分枝杆菌-胞内分枝杆菌和龟分枝杆菌引起的分枝杆菌病的首选药物。
